The Act Smart Campaign - Survivors Celebration Breakfast

I n s t i t u t e f or
Prostate Cancer
R e s e ar ch
Our Community Leaders Council
James Allchin, Retired, Microsoft Corp.
Rita Anderson, Community Leader
Stephen Anderson, Entrepreneur
Jeff Baker, Partner, Hornall Anderson
Design Works
Stanley H. Barer, J.D., Chairman Emeritus,
Saltchuk Enterprises
Ronald Behar, Chairman, Behar’s Furniture
and Carpets
Jim Blackmore, Director, General Steamship
Agencies
Campfire Boyz Foundation
Chris Carr, Executive Vice President, U.S. Retail,
Starbucks
Sid DeBoer, Founder and Executive Chairman,
Lithia Motors, Inc.
Mic R. Dinsmore, MBA, Former CEO
Port of Seattle
The Hon. Daniel J. Evans, Former Governor
of the State of Washington
Chairman, Daniel J. Evans Associates
Steve A. Fleischmann, Founding Event Chair;
Director, UW Foundation Board
Your Support
If we are going to defeat prostate cancer completely, your support is
critical. National funding for Act Smart won’t come until we show that
personalized medicine is possible. And for that to happen, we are almost
The Act Smart Campaign
Accelerating Cures for Prostate Cancer
completely reliant on individual support. We can start work today, but
only with your gift.
More Information
If you have any questions about Act Smart, please contact Colin Ware at
206.685.5412 or warec2@uw.edu, or Mike Rubin at 206.667.5377 or
mrubin@fhcrc.org. Thank you very much for your interest in Act Smart.
Mitchell H. Gold, M.D., Chairman,
CEO and Founder, Alpine Biosciences
Thomas F. Herche, President
United Warehouse Company
Mary R. Herche, Community Leader
Steven W. Hooper, Managing Director
and Founding Partner, Ignition Partners
Arthur D. Jackson, Jr., Vice President of
General Administration, Costco Wholesale
Chris Lloyd, Partner, Hey Advertising
Lynn Merritt, Vice President, Global Basketball
Sports Marketing, Nike
We believe it is possible to reduce and eventually eliminate
deaths from prostate cancer. Personalized medicine is the key
to achieving that goal, and understanding the genetics
underlying prostate cancer is the key to precision medicine.
Neiso Moscatel, Founder, Allegra Properties
Susan Nakagawa, Community Leader
Arlen I. (Arnie) Prentice, Chair, Kibble
and Prentice
Reid Porter, President, Porter Advisory Group
John C. Rudolf, President, Glacier Peak Capital
Michael Sandorffy, Owner, M. Sandorffy & Co.
Jeff Seely, Retired Founder, ShareBuilders
Securities Corp.
Samuel H. Smith, Ph.D., President Emeritus,
Washington State University
4 I The IPCR & Act Smart I Accelerating Cures for Prostate Cancer
April 2015
>
Act Smart is a campaign undertaken by the Institute for Prostate Cancer
Our Key Faculty
Research (IPCR), a joint venture of UW Medicine and Fred Hutchinson Cancer
Listed below are several key faculty connected with the IPCR. In all,
the IPCR includes approximately 40 researchers and physicians — in
fields ranging from urology to pathology to epidemiology — who
are dedicated to improving the lives of men with prostate cancer.
Research Center, that will help move personalized medicine forward in the
Pacific Northwest.
Great Strides in
Prostate Cancer Treatment
Act Smart: Putting Research
Advances into Practice
Men at risk of prostate cancer are far better off than they were
a few decades ago. PSA (prostate-specific antigen) testing and
the Gleason Index identify most prostate cancers. Surgery and
radiation offer successful cures for many. Active surveillance
spares thousands the costs and side effects of unnecessary
treatment.
Act Smart is a major campaign to pioneer personalized treatment
for prostate cancer. It has three components:
But even with these advances, 1 man in 36 dies of the disease.
Doctors still struggle to identify aggressive cancers and
recurrence is common. We have come a long way, but there
is work yet to be done.
Personalized Medicine:
The Key to Defeating
Prostate Cancer
Every man’s prostate cancer is unique. Tumors vary in size, speed
of growth and propensity to spread. Cancers respond differently
to treatment, and they show a range of mutations in their DNA.
This means that there will be no single cure for prostate cancer,
no magic bullet. Instead, success will come when treatment is
personalized for each patient based on their own, inherited
genetic traits and the genetic traits of their cancer.
Prohibitive costs once put personalized medicine out of reach.
But now, as the cost to sequence DNA drops, we are poised to
take this idea from the laboratory into the clinic.
Pictured on the front: some of the researchers, physicians and
other staff at UW Medicine and Fred Hutch whose work is at
the forefront of the fight against prostate cancer. From left to
right, are (top row): Keith Van Meter, Kenneth Russell, Bruce
Montgomery, Peter Nelson and Daniel Lin, and (bottom row):
Paul Lange, Leslie Butler, Elahe Mostaghel, Jonathan Wright,
Susan Treharne and William Ellis.
2 I The IPCR & Act Smart I Accelerating Cures for Prostate Cancer
Smart Research. Act Smart’s goals include developing a
clinical test that analyzes gene mutations specific to prostate
cancer, doubling the IPCR’s number of tumor avatars (human
tumors grown in mice) to more than 50, and cataloguing the
gene sequences of more than 500 tumors and effective treatments
for each. New therapies will be designed and tested directly on
avatars. Drugs effective on other cancers will be analyzed.
Smart Trials. Promising therapies will move quickly to trial.
Act Smart launches a new model for clinical tests, one that is
highly flexible and adapts to immediate findings. These adaptive trials increase the number of drugs tested and get to results
quickly. Cancer patients will gain access to successful new
therapies far faster than with traditional trials.
Smart Communities. Act Smart establishes new, statewide
partnerships among clinicians, researchers and patients. Research
results will be shared. More men from within and outside of
Seattle will be invited to join clinical trials. A new prevention
center will disseminate information on how to avoid prostate
cancer and help individuals understand their own personal risk
from the disease.
Researcher Janet
Stanford, Ph.D.
(right), pictured
with colleagues
Jonathan Wright,
M.D., and Marni
Stott-Miller,
Ph.D., is studying
how prostate
cancer is affected
by genetic risk
factors, among
other influences.
Paul Lange, M.D., FACS, Director, IPCR,
UW Professor Emeritus, Department of Urology,
and Affiliate Investigator, Fred Hutch. Focus:
genitourninary oncology, tumor markers,
reconstructive urologic surgery.
Patient care is an important part of the IPCR’s work. Celestia
Higano, M.D., Evan Yu, M.D., and R. Bruce Montgomery, M.D., are
pictured outside Seattle Cancer Care Alliance, a care consortium
that includes UW Medicine, Fred Hutch and Seattle Children’s.
The IPCR Advantage
The IPCR brings together a world-renowned team of more
than 40 scientists and clinicians whose mission is to understand the causes of prostate cancer and its progression, develop new prevention strategies, devise innovative diagnostics
and improve survival and quality of life.
IPCR researchers were at the forefront of PSA research and
the adoption of active surveillance treatment strategies. We
lead the field in identifying risk factors for prostate cancer,
including obesity, race and heredity, diet and smoking. We
also were among the first to identify the incredible genetic
diversity of prostate cancers — a finding which explains why
patients have such varying reactions to treatment.
The IPCR is also one of only a handful of institutions to
receive prestigious Specialized Programs for Research Excellence (SPORE) funding from the National Cancer Institute.
William Ellis, M.D., UW Professor, Department
of Urology. Focus: robot-assisted surgery.
Daniel Lin, M.D., UW Professor, Department of
Urology, Chief, Division of Urologic Oncology
at UW Medical Center, and Joint Associate
Member, Fred Hutch. Focus: genitourinary
oncology, early detection and prevention of
prostate cancer.
R. Bruce Montgomery, M.D., UW Professor
of Medicine, Division of Oncology, Clinical
Director, Seattle Cancer Care Alliance
Genitourninary/Prostate Oncology Program,
and Affiliate Member, Fred Hutch. Focus:
growth-factor signaling, drug resistance.
Peter Nelson, M.D., Chair, Scientific Steering
Committee-IPCR, Member, Fred Hutch, and
UW Professor of Medicine, Division of Oncology.
Focus: ICT therapies for early- and late-stage
prostate cancer.
Janet Stanford, Ph.D., MPH, BSN, Member,
Fred Hutch, UW Research Professor, Department
of Epidemiology, and UW Adjunct Research
Professor, Department of Urology. Focus: the
role of environmental, lifestyle and genetic
risk factors.
Robert Vessella, Ph.D., UW Professor Emeritus,
Department of Urology. Focus: tumor avatars.
Accelerating Cures for Prostate Cancer I The IPCR & Act Smart I 3
>
Act Smart is a campaign undertaken by the Institute for Prostate Cancer
Our Key Faculty
Research (IPCR), a joint venture of UW Medicine and Fred Hutchinson Cancer
Listed below are several key faculty connected with the IPCR. In all,
the IPCR includes approximately 40 researchers and physicians — in
fields ranging from urology to pathology to epidemiology — who
are dedicated to improving the lives of men with prostate cancer.
Research Center, that will help move personalized medicine forward in the
Pacific Northwest.
Great Strides in
Prostate Cancer Treatment
Act Smart: Putting Research
Advances into Practice
Men at risk of prostate cancer are far better off than they were
a few decades ago. PSA (prostate-specific antigen) testing and
the Gleason Index identify most prostate cancers. Surgery and
radiation offer successful cures for many. Active surveillance
spares thousands the costs and side effects of unnecessary
treatment.
Act Smart is a major campaign to pioneer personalized treatment
for prostate cancer. It has three components:
But even with these advances, 1 man in 36 dies of the disease.
Doctors still struggle to identify aggressive cancers and
recurrence is common. We have come a long way, but there
is work yet to be done.
Personalized Medicine:
The Key to Defeating
Prostate Cancer
Every man’s prostate cancer is unique. Tumors vary in size, speed
of growth and propensity to spread. Cancers respond differently
to treatment, and they show a range of mutations in their DNA.
This means that there will be no single cure for prostate cancer,
no magic bullet. Instead, success will come when treatment is
personalized for each patient based on their own, inherited
genetic traits and the genetic traits of their cancer.
Prohibitive costs once put personalized medicine out of reach.
But now, as the cost to sequence DNA drops, we are poised to
take this idea from the laboratory into the clinic.
Pictured on the front: some of the researchers, physicians and
other staff at UW Medicine and Fred Hutch whose work is at
the forefront of the fight against prostate cancer. From left to
right, are (top row): Keith Van Meter, Kenneth Russell, Bruce
Montgomery, Peter Nelson and Daniel Lin, and (bottom row):
Paul Lange, Leslie Butler, Elahe Mostaghel, Jonathan Wright,
Susan Treharne and William Ellis.
2 I The IPCR & Act Smart I Accelerating Cures for Prostate Cancer
Smart Research. Act Smart’s goals include developing a
clinical test that analyzes gene mutations specific to prostate
cancer, doubling the IPCR’s number of tumor avatars (human
tumors grown in mice) to more than 50, and cataloguing the
gene sequences of more than 500 tumors and effective treatments
for each. New therapies will be designed and tested directly on
avatars. Drugs effective on other cancers will be analyzed.
Smart Trials. Promising therapies will move quickly to trial.
Act Smart launches a new model for clinical tests, one that is
highly flexible and adapts to immediate findings. These adaptive trials increase the number of drugs tested and get to results
quickly. Cancer patients will gain access to successful new
therapies far faster than with traditional trials.
Smart Communities. Act Smart establishes new, statewide
partnerships among clinicians, researchers and patients. Research
results will be shared. More men from within and outside of
Seattle will be invited to join clinical trials. A new prevention
center will disseminate information on how to avoid prostate
cancer and help individuals understand their own personal risk
from the disease.
Researcher Janet
Stanford, Ph.D.
(right), pictured
with colleagues
Jonathan Wright,
M.D., and Marni
Stott-Miller,
Ph.D., is studying
how prostate
cancer is affected
by genetic risk
factors, among
other influences.
Paul Lange, M.D., FACS, Director, IPCR,
UW Professor Emeritus, Department of Urology,
and Affiliate Investigator, Fred Hutch. Focus:
genitourninary oncology, tumor markers,
reconstructive urologic surgery.
Patient care is an important part of the IPCR’s work. Celestia
Higano, M.D., Evan Yu, M.D., and R. Bruce Montgomery, M.D., are
pictured outside Seattle Cancer Care Alliance, a care consortium
that includes UW Medicine, Fred Hutch and Seattle Children’s.
The IPCR Advantage
The IPCR brings together a world-renowned team of more
than 40 scientists and clinicians whose mission is to understand the causes of prostate cancer and its progression, develop new prevention strategies, devise innovative diagnostics
and improve survival and quality of life.
IPCR researchers were at the forefront of PSA research and
the adoption of active surveillance treatment strategies. We
lead the field in identifying risk factors for prostate cancer,
including obesity, race and heredity, diet and smoking. We
also were among the first to identify the incredible genetic
diversity of prostate cancers — a finding which explains why
patients have such varying reactions to treatment.
The IPCR is also one of only a handful of institutions to
receive prestigious Specialized Programs for Research Excellence (SPORE) funding from the National Cancer Institute.
William Ellis, M.D., UW Professor, Department
of Urology. Focus: robot-assisted surgery.
Daniel Lin, M.D., UW Professor, Department of
Urology, Chief, Division of Urologic Oncology
at UW Medical Center, and Joint Associate
Member, Fred Hutch. Focus: genitourinary
oncology, early detection and prevention of
prostate cancer.
R. Bruce Montgomery, M.D., UW Professor
of Medicine, Division of Oncology, Clinical
Director, Seattle Cancer Care Alliance
Genitourninary/Prostate Oncology Program,
and Affiliate Member, Fred Hutch. Focus:
growth-factor signaling, drug resistance.
Peter Nelson, M.D., Chair, Scientific Steering
Committee-IPCR, Member, Fred Hutch, and
UW Professor of Medicine, Division of Oncology.
Focus: ICT therapies for early- and late-stage
prostate cancer.
Janet Stanford, Ph.D., MPH, BSN, Member,
Fred Hutch, UW Research Professor, Department
of Epidemiology, and UW Adjunct Research
Professor, Department of Urology. Focus: the
role of environmental, lifestyle and genetic
risk factors.
Robert Vessella, Ph.D., UW Professor Emeritus,
Department of Urology. Focus: tumor avatars.
Accelerating Cures for Prostate Cancer I The IPCR & Act Smart I 3
I n s t i t u t e f or
Prostate Cancer
R e s e ar ch
Our Community Leaders Council
James Allchin, Retired, Microsoft Corp.
Rita Anderson, Community Leader
Stephen Anderson, Entrepreneur
Jeff Baker, Partner, Hornall Anderson
Design Works
Stanley H. Barer, J.D., Chairman Emeritus,
Saltchuk Enterprises
Ronald Behar, Chairman, Behar’s Furniture
and Carpets
Jim Blackmore, Director, General Steamship
Agencies
Campfire Boyz Foundation
Chris Carr, Executive Vice President, U.S. Retail,
Starbucks
Sid DeBoer, Founder and Executive Chairman,
Lithia Motors, Inc.
Mic R. Dinsmore, MBA, Former CEO
Port of Seattle
The Hon. Daniel J. Evans, Former Governor
of the State of Washington
Chairman, Daniel J. Evans Associates
Steve A. Fleischmann, Founding Event Chair;
Director, UW Foundation Board
Your Support
If we are going to defeat prostate cancer completely, your support is
critical. National funding for Act Smart won’t come until we show that
personalized medicine is possible. And for that to happen, we are almost
The Act Smart Campaign
Accelerating Cures for Prostate Cancer
completely reliant on individual support. We can start work today, but
only with your gift.
More Information
If you have any questions about Act Smart, please contact Colin Ware at
206.685.5412 or warec2@uw.edu, or Mike Rubin at 206.667.5377 or
mrubin@fhcrc.org. Thank you very much for your interest in Act Smart.
Mitchell H. Gold, M.D., Chairman,
CEO and Founder, Alpine Biosciences
Thomas F. Herche, President
United Warehouse Company
Mary R. Herche, Community Leader
Steven W. Hooper, Managing Director
and Founding Partner, Ignition Partners
Arthur D. Jackson, Jr., Vice President of
General Administration, Costco Wholesale
Chris Lloyd, Partner, Hey Advertising
Lynn Merritt, Vice President, Global Basketball
Sports Marketing, Nike
We believe it is possible to reduce and eventually eliminate
deaths from prostate cancer. Personalized medicine is the key
to achieving that goal, and understanding the genetics
underlying prostate cancer is the key to precision medicine.
Neiso Moscatel, Founder, Allegra Properties
Susan Nakagawa, Community Leader
Arlen I. (Arnie) Prentice, Chair, Kibble
and Prentice
Reid Porter, President, Porter Advisory Group
John C. Rudolf, President, Glacier Peak Capital
Michael Sandorffy, Owner, M. Sandorffy & Co.
Jeff Seely, Retired Founder, ShareBuilders
Securities Corp.
Samuel H. Smith, Ph.D., President Emeritus,
Washington State University
4 I The IPCR & Act Smart I Accelerating Cures for Prostate Cancer
April 2015